Pharmacology of Dostarlimab: A Review
Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological ch...
Saved in:
| Main Authors: | Arnab Roy, Akash Chaurasiya |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krupanidhi College of Pharmacy
2022-09-01
|
| Series: | Journal of Pharmaceutical Research |
| Online Access: | https://jopcr.com/articles/pharmacology-of-dostarlimab-a-review |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dostarlimab A new hope for endometrial cancer patients in Pakistan
by: Maliha Khan
Published: (2024-09-01) -
Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report
by: Zaid Khamis, et al.
Published: (2025-08-01) -
Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review
by: Mateusz Kciuk, et al.
Published: (2025-06-01) -
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma
by: Claudia A. M. Fulgenzi, et al.
Published: (2025-07-01) -
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
by: Wei Guo, et al.
Published: (2022-03-01)